Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells 3,000 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $20.00, for a total value of $60,000.00. Following the transaction, the insider owned 67,845 shares in the company, valued at approximately $1,356,900. This represents a 4.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sharon Townson also recently made the following trade(s):

• On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $19.00, for a total transaction of $57,000.00.

Monte Rosa Therapeutics Trading Up 3.9%

Monte Rosa Therapeutics stock traded up $0.81 during midday trading on Thursday, hitting $21.66. 1,768,259 shares of the stock were exchanged, compared to its average volume of 1,328,242. The stock’s 50-day simple moving average is $18.79 and its 200 day simple moving average is $18.58. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.12 and a fifty-two week high of $25.77. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -14.64 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The firm had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Equities analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Guggenheim cut their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Wells Fargo & Company reduced their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Finally, JPMorgan Chase & Co. upped their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in Monte Rosa Therapeutics by 8.6% in the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after acquiring an additional 257,547 shares in the last quarter. Strs Ohio acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth about $566,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth about $778,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at approximately $172,000. Finally, CWM LLC grew its holdings in shares of Monte Rosa Therapeutics by 13.6% in the fourth quarter. CWM LLC now owns 29,444 shares of the company’s stock valued at $462,000 after purchasing an additional 3,536 shares in the last quarter. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.